The gross motor function measure™ is a valid and sensitive outcome measure for spinal muscular atrophy

Neuromuscular Disorders

Volumn 16, Issue 6, 2006, Pages 374-380

  Nelson, Leslie ^a   Owens, Hollis ^a   Hynan, Linda S ^b   Iannaccone, Susan T ^a,b,c   AmSMART Group, ^d  

^a TEXAS SCOTTISH RITE HOSPITAL FOR CHILDREN   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c CHILDREN S MEDICAL CENTER   (United States)

^d NONE

Author keywords

Clinical trials; Gross motor function measure; Outcome measures; Quantitative muscle testing; Spinal muscular atrophy

Indexed keywords

ADOLESCENT; ARTICLE; CHILD; CONTROLLED STUDY; FEMALE; HEALTH STATUS; HUMAN; INTERMETHOD COMPARISON; MALE; MOBILIZATION; MOTOR PERFORMANCE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUANTITATIVE ASSAY; SCORING SYSTEM; SENSITIVITY ANALYSIS; SPINAL MUSCULAR ATROPHY; VALIDATION PROCESS; WALKING AID;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; CLINICAL TRIALS; ENDPOINT DETERMINATION; FEMALE; HUMANS; MALE; MOTOR ACTIVITY; OUTCOME ASSESSMENT (HEALTH CARE); PSYCHOMOTOR PERFORMANCE; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; SPINAL MUSCULAR ATROPHIES OF CHILDHOOD;

EID: 33745027696     PISSN: 09608966     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nmd.2006.03.005     Document Type: Article

References (27)

1. DiDonato C.J., Ingraham S.E., Mendell J., et al. Deletions and conversion in spinal muscular atrophy patients: is there a relationship to severity?. Ann Neurol 41 (1997) 230-237
2. Andreassi C., Angelozzi C., Tiziano F.D., et al. Phenylbutyrate increases SMN expression in vitro: relevance for treatment of spinal muscular atrophy. Eur J Hum Genet (2003)
3. Brichta L., Hofmann Y., Hahnen E., et al. Valproic acid increases the SMN2 protein level: a well-known drug as a potential therapy for spinal muscular atrophy. Hum Mol Genet 12 (2003) 2481-2489
4. Haddad H., Cifuentes-Diaz C., Miroglio A., Roblot N., Joshi V., and Melki J. Riluzole attenuates spinal muscular atrophy disease progression in a mouse model. Muscle Nerve 28 (2003) 432-437
5. Russman B.S., Iannaccone S.T., and Samaha F.J. A phase one trial of riluzole in spinal muscular atrophy. Arch Neurol (2003) 60
6. Kinali M., Mercuri E., Main M., et al. Pilot trial of albuterol in spinal muscular atrophy. Neurology 59 4 (2002) 609-610
7. Grzeschik S.M., Ganta M., Prior T.W., Heavlin W.D., and Wang C.H. Hydroxyurea enhances SMN2 gene expression in spinal muscular atrophy cells. Ann Neurol 58 (2005) 194-202
8. Markowitz JA, Coovert DD, Schussler K, Burghes AHM, Fischbeck KH, Taylor JP. Valproic acid increases SMN levels in SMA fibroblasts, Sixth Annual International Spinal Muscular Atrophy Research Group Meeting, 2002;6:35.
9. Andreassi C., Jarecki J., Zhou J., et al. Aclarubicin treatment restores SMN levels to cells derived from type 1 spinal muscular atrophy patients. Hum Mol Genet 10 (2001) 2841-2849
10. Sumner C.J., Huynh T.N., Markowitz J.A., et al. Valproic acid increases SMN levels in spinal muscular atrophy patient cells. Ann Neurol 54 (2003) 647-654
11. Mercuri E., Bertini E., Messina S., et al. Pilot trial of phenylbutyrate in spinal muscular atrophy. Neuromuscul Disord 14 (2004) 130-135
12. Iannaccone S.T., Hynan L.S., and Am S.M.A.R.T. Reliability of four outcome measures in pediatric spinal muscular atrophy. Arch Neurol 60 (2003) 1130-1136
13. Russell D.J., Rosenbaum P.L., Cadman D.T., Gowland C., Hardy S., and Jarvis S. The gross motor function measure: a means to evaluate the effects of physical therapy. Dev Med Chil Neurol 31 (1989) 341-352
14. Palisano R.J., Hanna S.E., Rosenbaum P.L., et al. Validation of a model of gross motor function for children with cerebral palsy. Phys Ther 80 (2000) 974-985
15. Rosenbaum P.L., Walter S.D., Hanna S.E., et al. Prognosis for gross motor function in cerebral palsy: creation of motor development curves. J Am Med Assoc 288 (2002) 1357-1363
16. McCarthy M.L., Silberstein C.E., Atkins E.A., Harryman S.E., Sponseller P.D., and Hadley-Miller N.A. Comparing reliability and validity of pediatric instruments for measuring health and well-being of children with spastic cerebral palsy. Dev Med Child Neurol 44 (2002) 468-476
17. Ketelaar M., Vermeer A., and Helders P.J. Functional motor abilities of children with cerebral palsy: a systematic literature review of assessment measures. Clin Rehabil 12 (1998) 369-380
18. Russell D.J., Avery L.M., Rosenbaum P.L., Raina P.S., Walter S.D., and Palisano R.J. Improved scaling of the gross motor function measure for children with cerebral palsy: evidence of reliability and validity. Phys Ther 80 (2000) 873-885
19. Fattal-Valevski A., Giladi N., Domanievitz D., et al. Parameters for predicting favorable responses to botulinum toxin in children with cerebral palsy. J Child Neurol 17 (2002) 272-277
20. Iannaccone S.T., and Am S.M.A.R.T. Outcome measures for pediatric spinal muscular atrophy. Arch Neurol 59 (2002) 1445-1450
21. Aitkens S., Lord J., Bernauer E., Fowler W.M., Lieberman J.S., and Berck P. Relationship of manual muscle testing to objective strength measurements. Muscle Nerve 12 (1989) 173-177
22. Barker L., Smith C., Perkins B., et al. Clinical trials in spinal muscular atrophy: protocol development and reliability of quantitative strength assessment method. J Neurol Rehabil 6 (1992) 175-183
23. Escolar D.M., Henricson E.K., Mayhew J., et al. Clinical evaluator reliability for quantitative and manual muscle testing measures of strength in children. Muscle Nerve 24 (2001) 787-793
24. Mathieu J., Boivin H., and Richards C.L. Quantitative motor assessment in myotonic dystrophy. Can J Neurol Sci 30 (2003) 129-136
25. Iannaccone S.T., Hynan L.S., Leshner R., Russman B.S., Smith S.A., and Wong B. Randomized creatine trial in childhood spinal muscular atrophy. Ann Neurol 56 (2004) S88
26. Miller R.G., Moore D.H., Dronsky V., et al. A placebo-controlled trial of gabapentin in spinal muscular atrophy. J Neurol Sci 191 (2001) 127-131
27. American Psychological Association, 1985 ed. Standards for educational and psychological testing. Washington, DC: American Psychological Association: p 9 and 19.